CNS Stimulant·Psychiatry - ADHD & Stimulants

methYLPHENIDATE

Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy

S8Authority requiredPBSS8 STIMULANTRitalin (IR/LA), Concerta (OROS XR), Ritalin 10+2

No source link confirmed for this record yet. Its own source notes are under Additional.

At a glance

Max Dose

80 mg/day

Half-life

2–3 h (IR)

Caution: BP/HR

MONITOR

Caution: Misuse Risk

HIGH

Cautions

Avoid / Cautions

Glaucoma, severe hypertension, symptomatic cardiovascular disease, hyperthyroidism, active psychosis, concurrent MAOIs. Pregnancy Category B3.

Where it stands

Rapid Summary

Overview

Central Nervous System stimulant. Blocks dopamine and noradrenaline reuptake. The first-line therapy for ADHD. Highly effective but strictly controlled due to abuse potential.

Clinical Focus

Elevates blood pressure and heart rate. Must monitor cardiovascular status, especially in adults.

Bottom Line

Methylphenidate is a first-line stimulant for ADHD with rapid onset and multiple formulations, but is a Schedule 8 controlled substance with cardiovascular monitoring requirements and abuse potential.

Formulation & Access

Brand Names

Ritalin (IR/LA), Concerta (OROS XR), Ritalin 10

Oral Routes

Do not crush

Tablets IR (10 mg). Capsules LA (10, 20, 30, 40 mg). OROS osmotic tablets (18, 27, 36, 54 mg). Do NOT crush XR forms.

Prescribing & PBS

Highly Restricted (S8). Authority Required (PBS). Strict state-based prescribing rules (Requires Paediatrician or Psychiatrist authorisation).

Indications & Use

Primary

PBSTGA

Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy.

Off-Label

OFF

Severe refractory depression (specialist only), fatigue in terminal cancer.

Clinical Place

The foundational treatment for ADHD. Improves focus, reduces impulsivity, and paradoxically calms hyperactive patients.

Quick reference

Class & Role

CNS Stimulant — Central Nervous System stimulant.

Route / Formulation

Tablets IR (10 mg). Capsules LA (10, 20, 30, 40 mg). OROS osmotic tablets (18, 27, 36, 54 mg). Do NOT crush XR forms. (Ritalin (IR/LA), Concerta (OROS XR), Ritalin 10)

Usual Dose & Max

PO 5-10 mg BD to TDS. Titrate up weekly. Doses given morning and midday to prevent severe insomnia. Max 80 mg/day (Varies slightly based on specific long-acting formulations and specialist state guidelines).

Key Indication Doses

ADHD (Immediate Release): PO 5-10 mg BD to TDS. Titrate up weekly. Doses given morning and midday to prevent severe insomnia. ADHD (Extended Release): PO 18-54 mg OD (Concerta) OR 10-40 mg OD (Ritalin LA). Taken strictly in the morning. Narcolepsy: PO 10-60 mg/day in divided doses.

Best Uses

Key Risks

Cardiovascular: Tachycardia, hypertension, palpitations. Rare risk of sudden cardiac death in patients with structural heart defects. Neurological: Severe insomnia, anxiety, agitation, tics, psychosis/mania (if bipolar), high addiction/abuse potential. Metabolic/GI: Severe appetite suppression, weight loss, stunted growth in children.

Key Interactions

MAOIs (Fatal hypertensive crisis). TCAs, SNRIs (Synergistic cardiovascular toxicity).

Monitoring

Baseline and 6-monthly BP, HR, Weight, and Height (in children). Consider baseline ECG if there is a family history of sudden cardiac death.

Clinical Pearl

Immediate release (Ritalin 10) wears off abruptly after 3-4 hours, causing a severe 'rebound' crash of irritability and hyperactivity. Transitioning to long-acting formulations (Concerta) smooths this out completely.

Access

Authority requiredRitalin (IR/LA), Concerta (OROS XR), Ritalin 1010 mg tablet

Brand: Ritalin (IR/LA), Concerta (OROS XR), Ritalin 10
PBS status: Authority required
Formulation: Tablets IR (10 mg). Capsules LA (10, 20, 30, 40 mg). OROS osmotic tablets (18, 27, 36, 54 mg). Do NOT crush XR forms.

From this page

No calculator, monitoring schedule or factsheet is linked to this medicine page yet.